Form 8-K Aclaris Therapeutics, For: Nov 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Comments on Aclaris Therapeutics (ACRS), Shares up 33% Today, Up 245% Over Past 30 Days
November 19, 2024 11:07 AM ESTGoldman Comments on Aclaris Therapeutics (NASDAQ: ACRS)
The analyst comments "This morning, ACRS announced it has entered into a license agreement with Biosion for global rights (excluding China) to BSI-045B (also known as TQC2731), an anti-TSLP monoclonal antibody (mAb), and BSI-502, an anti-TSLP plus anti-IL4R... More
Leerink Partners Upgrades Aclaris Therapeutis (ACRS) to Outperform, Shares +20% in Premarket Session
November 19, 2024 7:06 AM EST(Updated - November 19, 2024 7:19 AM EST)
Leerink Partners analyst Thomas J. Smith upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Market Perform to Outperform with a price target of $7.00 (from $2.00).
The analyst comments "We are upgrading ACRS to Outperform (from Market Perform) and raising our PT... More
Piper Sandler Upgrades Aclaris Therapeutis (ACRS) to Overweight, PT $13
November 18, 2024 2:54 PM ESTPiper Sandler analyst Christopher Raymond upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Neutral to Overweight with a price target of $13.00 (from $3.00).
The analyst comments "Upgrading ACRS shares to Overweight after what we see as a transformative deal to acquire two novel I&I... More
Stifel Reiterates Hold Rating on Aclaris Therapeutis (ACRS)
November 18, 2024 12:34 PM ESTStifel analyst Alex Thompson reiterated a Hold rating and $3.00 price target on Aclaris Therapeutis (NASDAQ: ACRS)
The analyst comments "Aclaris announced a licensing agreement with Biosion to acquire ex-China rights to a clinical stage TSLP mAb (BSI-045B) and a preclinical TSLPxIL-4R bispecific (BSI-502). The... More
